Recent preclinical research demonstrates that bone marrow transplants from younger mice can reverse key signs of biological aging and reduce amyloid-beta accumulation in older mouse models of Alzheimer’s disease. According to researchers at the Third Military Medical University in Chongqing, China, the intervention improved overall cognitive function in the treated animals, offering new insight into how hematopoietic stem cells influence neurological health.
The Impact of Aging on Bone Marrow Stem Cells
Bone marrow houses hematopoietic stem cells responsible for generating the diverse array of blood cells required by the immune system. As humans and animals age, the diversity of these stem cells naturally declines through a process known as clonal hematopoiesis. During this mechanism, specific stem cells acquire mutations that drive rapid proliferation, crowding out other cell lines and reducing immune system versatility. Rizwan Bashir, MD, a neurologist at Acia Orthopedics who was not involved in the study, noted to Medical News Today that Alzheimer’s disease is heavily tied to biological aging due to cumulative cellular damage, oxidative stress, and the gradual failure of metabolic waste clearance.
Gene Expression and Immune Cell Restoration
To evaluate whether restoring younger stem cells could combat brain aging, investigators utilized 9-month-old and 2-month-old mice engineered to model Alzheimer’s disease. The researchers transplanted bone marrow from the 2-month-old mice into a group of 9-month-old transgenic mice, while a control group of 9-month-old mice received bone marrow from donors of the same age. Gene expression analysis revealed that older mice exhibited distinct up-regulated pathways related to mitochondrial function and down-regulated pathways associated with epigenetic regulation and immune processes. Following the bone marrow transplant from younger donors, the gene expression profiles in the older mice reverted toward youthful patterns. T-cells and monocytes emerged as the specific immune cell populations most significantly impacted by the procedure.
TREM2-Independent Pathways in Disease Modification
The bone marrow findings align with broader scientific inquiries into how peripheral immune cells communicate with the central nervous system during neurodegeneration. In a related study published in Nature Aging, investigators including Raz Dvir-Szternfeld and Michal Schwartz examined monocyte-derived macrophages (MDMs) in mouse models of amyloidosis. Their findings showed that targeting the programmed cell death ligand-1 (PD-L1) immune checkpoint induced cognitive improvement and reduced water-soluble amyloid-beta 1-42 levels without directly altering overall amyloid plaque burden. Single-cell RNA sequencing revealed that these MDMs expressed a unique set of scavenger receptors independently of TREM2, a receptor traditionally linked to microglial activation in Alzheimer’s models. Blocking monocyte trafficking with an anti-CCR2 antibody completely nullified the cognitive benefits of the PD-L1 treatment, highlighting the active role peripheral immune cells play in modifying disease pathology.
Future Directions and Clinical Questions
While the preclinical results in animal models demonstrate clear reductions in neuronal degeneration, behavioral deficits, and amyloid-beta accumulation, translating these findings to human patients presents significant challenges.
Keep reading